IMNM Immunome Inc.

Nasdaq immunome.com


$ 18.01 $ 0.60 (3.41 %)    

Friday, 21-Nov-2025 09:55:51 EST
QQQ $ 588.24 $ 1.08 (0.18 %)
DIA $ 459.01 $ -0.46 (-0.1 %)
SPY $ 655.40 $ 0.39 (0.06 %)
TLT $ 89.49 $ -0.17 (-0.19 %)
GLD $ 374.59 $ 0.60 (0.16 %)
$ 17.51
$ 17.58
$ 18.05 x 8
$ 18.25 x 11
$ 17.58 - $ 18.06
$ 5.15 - $ 18.94
850,407
na
1.61B
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-19-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stephens--co-maintains-overweight-on-immunome-raises-price-target-to-33

Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight and raises the price target f...

 immunome-q3-eps-065-misses-058-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.58) by...

 immunome-presented-preclinical-data-showing-its-proprietary-antibody-drug-conjugate-payload-hc74-overcomes-multiple-mechanisms-of-adc-resistance-including-payload-efflux-and-target-heterogeneity-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer th...

 goldman-sachs-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Tar...

 craig-hallum-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 guggenheim-reiterates-buy-on-immunome-maintains-25-price-target

Guggenheim analyst Michael Schmidt reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $25 price target.

 evercore-isi-group-initiates-coverage-on-immunome-with-outperform-rating-announces-price-target-of-18

Evercore ISI Group analyst Cory Kasimov initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces ...

 jp-morgan-maintains-overweight-on-immunome-lowers-price-target-to-22

JP Morgan analyst Brian Cheng maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $23 to $22.

 immunome-q1-eps-052-beats-068-estimate-sales-293m-beat-28571k-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.68) by 2...

 lake-street-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-23

Lake Street analyst Chad Messer initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 wedbush-reiterates-outperform-on-immunome-maintains-33-price-target

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.

 stephens--co-reiterates-overweight-on-immunome-maintains-30-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Immunome (NASDAQ:IMNM) with a Overweight and maintains $30 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION